Crispr Therapeutics Q4 Earnings Review: Ignore The Lack Of Revenues, Buy The Future
Crispr Therapeutics AG has revenue declines but holds strong financials. Promising Sickle Cell therapy & 2025 data readouts ...
Stalled microbiomes: Study reveals cystic fibrosis disrupts early gut development in infants
Findings from a new Dartmouth-led study, published in the journal mBio, highlight key differences in the gut microbiome ...
The Lancet21h
Patient with cystic fibrosis not diagnosed until age 23 years now treated with the new triple therapy Trikafta
The effect of cystic fibrosis on many organs and the frequent lung infections means that it is mostly diagnosed in childhood. Somehow, for Verônica Stasiak Bednarczuk, that diagnosis did not arrive ...
Kiwi runner breathes fresh air into what's possible with cystic fibrosis
Aucklander Ben Prince-Saxon is pushing the boundaries of what's possible living with cystic fibrosis.
Healio8h
Positive topline data reported in phase 3 trial of nerandomilast in progressive PF
Adults with progressive pulmonary fibrosis met the primary endpoint of absolute change in FVC with 52-week oral nerandomilast ...
CRISPR: From Discovery To Clinic—And Charting A Path Forward
No doubt 2025 will usher in many more advances in CRISPR therapies, thanks to the FDA’s new Platform Technology Designation ...
Earnings call transcript: Devyser Diagnostics posts first profitable quarter in Q4 2024
Devyser Diagnostics AB (DVYSR) reported its first profitable quarter as a public company in Q4 2024, with revenue reaching SEK 64.2 million, marking a 41.5% year-over-year increase. This achievement ...
European Medical Journal8h
Pseudomonas Infection Triggers Lung Transplant Rejection Through Immune Disruption
Pseudomonas aeruginosa triggers lung transplant rejection by killing regulatory T cells, revealing new targets for AMR ...